Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer

Content

• 1 Executive Summary
• 2 Methodologies
• 3 Table of Contents
  • 3.1 List of Figures
  • 3.2 List of Tables
  • 3.3 List of Boxes
• 4 Antibody Drug Target Analysis in Oncology: What and Where Are We Targeting?
• 5 Antibody Drug Targets by Molecular Function
  • 5.1 Carboxypeptidase Activity Targets
  • 5.2 Catalytic Activity Targets
  • 5.3 Cell Adhesion Molecule Activity Targets
  • 5.4 Chaperone Activity Targets
  • 5.5 Chemokine Activity Targets
  • 5.6 Cofactor Binding Targets
  • 5.7 Complement Activity Targets
  • 5.8 Cytokine Activity Targets
  • 5.9 DNA Topoisomerase Activity Targets
  • 5.10 Extracellular Matrix Structural Constituent Targets
  • 5.11 G-protein Coupled Receptor Activity Targets
  • 5.12 Growth Factor Activity Targets
  • 5.13 Hormone Activity Targets
  • 5.14 Hydrolase Activity Targets
  • 5.15 Intracellular Ligand-gated Ion Channel Activity Targets
  • 5.16 Metallopeptidase Activity Targets
  • 5.17 MHC Class I Receptor Activity Targets
• 8 Triple Analysis Report| BioSeeker Group AB
  • 5.18 Molecular Function Unknown Targets
  • 5.19 Oxidoreductase Activity Targets
  • 5.20 Peptide Hormone Targets
  • 5.21 Protease Inhibitor Activity Targets
  • 5.22 Protein Binding Targets
  • 5.23 Receptor Activity Targets
  • 5.24 Receptor Binding Targets
  • 5.25 Receptor Signaling Complex Scaffold Activity Targets
  • 5.26 Receptor Signaling Protein Tyrosine Phosphatase Activity Targets
  • 5.27 RNA-directed DNA polymerase Activity Targets
  • 5.28 Serine-type Peptidase Activity Targets
  • 5.29 T Cell Receptor Activity Targets
  • 5.30 Translation Regulator Activity Targets
  • 5.31 Transmembrane Receptor Activity Targets
  • 5.32 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
  • 5.33 Transporter Activity Targets
  • 5.34 Unclassified Targets
• 6 Antibody Drugs Targeting Signaling Pathways
  • 6.1 Alpha6 Beta4 Integrin Signaling Pathway
    • 6.1.1 Description of Pathway
    • 6.1.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
  • 6.2 Androgen Receptor Signaling Pathway
    • 6.2.1 Description of Pathway
    • 6.2.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
  • 6.3 B Cell Receptor Signaling Pathway
    • 6.3.1 Description of Pathway
    • 6.3.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
  • 6.4 EGFR1 Signaling Pathway
    • 6.4.1 Description of Pathway
    • 6.4.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
  • 6.5 IL-2 Signaling Pathway
    • 6.5.1 Description of Pathway
    • 6.5.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
  • 6.6 IL-4 Signaling Pathway
    • 6.6.1 Description of Pathway
    • 6.6.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
  • 6.7 IL-6 Signaling Pathway
    • 6.7.1 Description of Pathway
    • 6.7.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
  • 6.8 Kit Receptor Signaling Pathway
    • 6.8.1 Description of Pathway
    • 6.8.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
  • 6.9 Notch Signaling Pathway
    • 6.9.1 Description of Pathway
    • 6.9.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
  • 6.10 T Cell Receptor Signaling Pathway
    • 6.10.1 Description of Pathway
    • 6.10.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
  • 6.11 TGF-beta Receptor Signaling Pathway
    • 6.11.1 Description of Pathway
    • 6.11.2 Antibody Drugs byTarget, Developmental Stage, and Cancer Type
  • 6.12 TNF-alpha Signaling Pathway
    • 6.12.1 Description of Pathway
    • 6.12.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
  • 6.13 Wnt Signaling Pathway
    • 6.13.1 Description of Pathway
    • 6.13.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
• 7 Antibodies Targeting Cancer Stem Cells
• 8 Targets of Antibody Conjugates
• 9 Antibody Drug Targets by Three Major Non Immunological Therapeutic Effects
  • 9.1 Anti-Angiogenesis
  • 9.2 Apoptosis
  • 9.3 Protein Kinase Inhibitors
• 10 Antibody Targets and Drugs by Cancer Indications
  • 10.1 Basal Cell Cancer
  • 10.2 Biliary Cancer
  • 10.3 Bladder Cancer
  • 10.4 Bone Cancer
  • 10.5 Brain Cancer
  • 10.6 Breast Cancer
  • 10.7 Cervical Cancer
  • 10.8 Cervical Dysplasia
  • 10.9 Colorectal Cancer
  • 10.10 Endometrial Cancer
  • 10.11 Esophageal Cancer
  • 10.12 Fallopian Tube Cancer
  • 10.13 Gastrointestinal Cancers
  • 10.14 Head and Neck Cancer
  • 10.15 Leukemias
  • 10.16 Liver Cancer
  • 10.17 Lung Cancers
  • 10.18 Lymphomas
  • 10.19 Melanoma
  • 10.20 Mesothelioma
  • 10.21 Myelodysplastic syndrome
  • 10.22 Myelomas
  • 10.23 Nasopharyngeal Cancer
  • 10.24 Oesophageal Cancer
  • 10.25 Ovarian Cancer
  • 10.26 Pancreatic Cancer
  • 10.27 Peritoneal Cancer
  • 10.28 Prostate Cancer
  • 10.29 Renal Cancers
  • 10.30 Sarcomas
  • 10.31 Thyroid Cancer
• 11 Expression Profiles of Antibody Drug Targets
  • 11.1 Human Tissues and Cancer Tissues
  • 11.2 Cancer Lines and Cells
• 12 Breast Cancer: An Introduction
  • 12.1 Disease Definitions
  • 12.2 Etiology
  • 12.3 Epidemiology
  • 12.4 Prognosis
• 13 Current Treatment Strategies of Breast cancer
  • 13.1 Localized Disease
  • 13.2 Advanced Disease
• 14 Progress in Current Breast Cancer Treatment Strategies
  • 14.1 Hormone Based Therapies
  • 14.2 Antibodies
  • 14.3 Chemotherapy
  • 14.4 Chemotherapy
• 15 Key Therapeutic Strategies for Future Breast Cancer Therapies
  • 15.1 Therapeutic Type, Targets & Mechanisms
• 16 Competitive Landscape in Breast Cancer Drug Development: The Late Stage Pipeline
  • 16.1 The Epothilones
  • 16.2 Cell Cycle & Apoptosis
  • 16.3 Protein Kinase Inhibitors
  • 16.4 Immunotherapy
• 17 Current Drug Development for Breast Cancer: The Early Stage Pipeline
  • 17.1 DNA Targeting
  • 17.2 FTIs
  • 17.3 Antisense
  • 17.4 New Hormone Modulators
  • 17.5 Other
• 18 Prostate Cancer: An Introduction
  • 18.1 Disease Definitions
  • 18.2 Etiology & Pathophysiology
  • 18.3 Epidemiology
  • 18.4 Prognosis
• 19 Current Prostate Cancer Treatment Strategies
  • 19.1 Localized Disease
    • 19.1.1 Locally Advanced Prostate Cancer
  • 19.2 Metastatic Prostate Cancer
    • 19.2.1 Hormone-Sensitive Metastatic Prostate Cancer
    • 19.2.2 Hormone-Refractory or Recurrent Metastatic Prostate Cancer
• 20 Progress in Current Prostate CancerTreatment Strategies
  • 20.1 Long-Term Follow-up Data not yet Been Published
  • 20.2 Significant Reduced Risk of Distant Metastases
  • 20.3 Adverse Events
  • 20.4 No Difference in Overall Survival
  • 20.5 Cross-over Design an Optimal Option?
  • 20.6 Death due to Liver Failure
  • 20.7 Survival Benefit
  • 20.8 Subdermal Implant
  • 20.9 No FDA Approval
  • 20.10 No Improvement in 5-year Disease-Free Survival
  • 20.11 Effective Secondary Hormonal Therapy?
  • 20.12 Synery in Combination
• 21 Key Therapeutic Strategies for Future Prostate Cancer Therapies
  • 21.1 Therapeutic Type, Targets & Mechanisms
• 22 Competitive Landscape in Prostate Cancer Drug Development: The Late Stage Pipeline
  • 22.1 Reduced Prostate Cancer Risk
  • 22.2 High Activity in Metastatic AIPC Patients
  • 22.3 Absence of Severe Toxicities
  • 22.4 Waiting for Data
  • 22.5 Probability of Regulatory Approval?
  • 22.6 Co-development and License Agreement
  • 22.7 Improves Predicted Survival?
  • 22.8 Slow Progress & Development Partners
  • 22.9 Exclusive License Agreement
• 23 Current Prostate Cancer Drug Development: The Early Stage Pipeline
  • 23.1 New Data?
  • 23.2 Terminated Study
  • 23.3 More Than 50% PSA decline
  • 23.4 Safety and Tolerability
  • 23.5 Terminated?
  • 23.6 Marker of Drug Effect
  • 23.7 Preliminary Results for a Tyrosine Kinase Inhibitor
  • 23.8 No Activity in Monotherapy
  • 23.9 Dramatic Disappearance of Bone Metastatic Lesions
  • 23.10 PSA Response - Anthracycline
• 24 Disclaimer
• 25 Drug Index
• 26 Company Index
• 27 Appendix I: Antibody Targets by Companies
• 3.1 List of Figures
  • Figure 1: Antibody Pipeline Maturity by Molecular Function Classes of Targets 1(3)
  • Figure 2: Antibody Pipeline Maturity by Molecular Function Classes of Targets 2(3)
  • Figure 3: Antibdody Pipeline Maturity by Molecular Function Classes of Targets 3(3)
  • Figure 4: Pipeline Maturation of Carboxypeptidase Activity Targets
  • Figure 5: Number of Antibody Drugs per Cancer Indication and Carboxypeptidase Activity Target
  • Figure 6: Pipeline Maturation of Catalytic Activity Targets
  • Figure 7: Number of Antibody Drugs per Cancer Indication and Catalytic Activity Target
  • Figure 8: Pipeline Maturation of Cell Adhesion Molecule Activity Targets
  • Figure 9: Number of Antibody Drugs per Cancer Indication and Cell Adhesion Molecule Activity Target
  • Figure 10: Pipeline Maturation of Chaperone Activity Targets
  • Figure 11: Number of Antibody Drugs per Cancer Indication and Chaperone Activity Target
  • Figure 12: Pipeline Maturation of Chemokine Activity Targets
  • Figure 13: Number of Antibody Drugs per Cancer Indication and Chemokine Activity Target
  • Figure 14: Pipeline Maturation of Cofactor Binding Targets
  • Figure 15: Number of Antibody Drugs per Cancer Indication and Cofactor Binding Target
  • Figure 16: Pipeline Maturation of Complement Activity Targets
  • Figure 17: Number of Antibody Drugs per Cancer Indication and Complement Activity Target
  • Figure 18: Pipeline Maturation of Cytokine Activity Targets
  • Figure 19: Number of Antibody Drugs per Cancer Indication and Cytokine Activity Target
  • Figure 20: Pipeline Maturation of DNA Topoisomerase Activity Targets
  • Figure 21: Number of Antibody Drugs per Cancer Indication and DNA Topoisomerase Activity Target
  • Figure 22: Pipeline Maturation of Extracellular Matrix Structural Constituent Targets
  • Figure 23: Number of Antibody Drugs per Cancer Indication and Extracellular Matrix Structural Constituent Target
  • Figure 24: Pipeline Maturation of G-protein Coupled Receptor Activity Targets
  • Figure 25: Number of Antibody Drugs per Cancer Indication and Extracellular G-protein Coupled Receptor Activity Target
  • Figure 26: Pipeline Maturation of Growth Factor Activity Targets
  • Figure 27: Number of Antibody Drugs per Cancer Indication and Extracellular Growth Factor Activity Target
  • Figure 28: Pipeline Maturation of Hormone Activity Targets
  • Figure 29: Number of Antibody Drugs per Cancer Indication and Hormone Activity Target
  • Figure 30: Pipeline Maturation of Hydrolase Activity Targets
  • Figure 31: Number of Antibody Drugs per Cancer Indication and Hydrolase Activity Target
  • Figure 32: Pipeline Maturation of Ligand-gated Ion Channel Activity Targets
  • Figure 33: Number of Antibody Drugs per Cancer Indication and Intracellular Ligand-gated Ion Channel Activity Target
  • Figure 34: Pipeline Maturation of Metallopeptidase Activity Targets
  • Figure 35: Number of Antibody Drugs per Cancer Indication and Intracellular Metallopeptidase Activity Target
  • Figure 36: Pipeline Maturation of MHC Class I Receptor Activity Targets
  • Figure 37: Number of Antibody Drugs per Cancer Indication and MHC Class I Receptor Activity Target
  • Figure 38: Pipeline Maturation of Molecular Function Unknown Targets
  • Figure 39: Number of Antibody Drugs per Cancer Indication and Molecular Function Unknown Target
  • Figure 40: Pipeline Maturation of Oxidoreductase Activity Targets
  • Figure 41: Number of Antibody Drugs per Cancer Indication and Oxidoreductase Activity Target
  • Figure 42: Pipeline Maturation of Peptide Hormone Targets
  • Figure 43: Number of Antibody Drugs per Cancer Indication and Peptide Hormone Target
  • Figure 44: Pipeline Maturation of Protease inhibitor Activity Targets
  • Figure 45: Number of Antibody Drugs per Cancer Indication and Protease Inhibitor Activity Target
  • Figure 46: Pipeline Maturationof Protein Binding Targets
  • Figure 47: Number of Antibody Drugs per Cancer Indication and Protein Binding Target
  • Figure 48: Pipeline Maturation of Receptor Activity Targets 1 (2)
  • Figure 49: Number of Antibody Drugs per Cancer Indication and Receptor Activity Target 1(2)
  • Figure 50: Pipeline Maturation of Receptor Activity Targets 2 (2)
  • Figure 51: Number of Antibody Drugs per Cancer Indication and Receptor Activity Target 2(2)
  • Figure 52: Pipeline Maturationof Receptor Binding Targets
  • Figure 53: Number of Antibody Drugs per Cancer Indication and Receptor Binding Target
  • Figure 54: Pipeline Maturation of Receptor Signaling Complex Scaffold Activity Targets
  • Figure 55: Number of Antibody Drugs per Cancer Indication and Receptor Signaling Complex Scaffold Activity Target
  • Figure 56: Pipeline Maturation of by Receptor Signaling Protein Tyrosine Phosphatase Activity Targets
  • Figure 57: Number of Antibody Drugs per Cancer Indication and Receptor Signaling Protein Tyrosine Phosphatase Activity Target
  • Figure 58: Pipeline Maturation of RNA-directed DNA polymerase Activity Targets
  • Figure 59: Number of Antibody Drugs per Cancer Indication and RNA-directed DNA polymerase Activity Target
  • Figure 60: Pipeline Maturation of Serine-type Peptidase Activity Targets
  • Figure 61: Number of Antibody Drugs per Cancer Indication and RNA Serine-type Peptidase Activity Target
  • Figure 62: Pipeline Maturation of T cell Receptor Activity Targets
  • Figure 63: Number of Antibody Drugs per Cancer Indication and T cell Receptor Activity Target
  • Figure 64: Pipeline Maturation of Translation Regulator Activity Targets
  • Figure 65: Number of Antibody Drugs per Cancer Indication and Translation Regulator Activity Target
  • Figure 66: Pipeline Maturation of Transmembrane Receptor Activity Targets
  • Figure 67: Number of Antibody Drugs per Cancer Indication and Transmembrane Receptor Activity Target
  • Figure 68: Pipeline Maturation of Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
  • Figure 69: Number of Antibody Drugs per Cancer Indication and Transmembrane Receptor Protein Tyrosine Kinase Activity Target
  • Figure 70: Pipeline Maturation of Transporter Activity Targets
  • Figure 71: Number of Antibody Drugs per Cancer Indication and Transporter Activity Target
  • Figure 72: Pipeline Maturation of Unclassified Targets
  • Figure 73: Number of Antibody Drugs per Cancer Indication and Unclassified Target
  • Figure 74: Antibody Pipeline Comparison of Targeted Signaling Pathways in Oncology
  • Figure 75: Pipeline Maturation of Immunoconjugated Antibody Targets
  • Figure 76: Number of Immunoconjugated Antibody Drugs per Cancer Indication and Target
• 3.2 List of Tables
  • Table 1: Molecular Functions versus Oncology Antibody Drug Targets
  • Table 2: Cancer Antibody Pipeline Listed by Carboxypeptidase Activity Targets
  • Table 3: Cancer Antibody Pipeline Listed by Catalytic Activity Targets
  • Table 4: Cancer Antibody Pipeline Listed by Cell Adhesion Molecule Activity Targets
  • Table 5: Cancer Antibody Pipeline Listed by Chaperone Activity Targets
  • Table 6: Cancer Antibody Pipeline Listed by Chemokine Activity Targets
  • Table 7: Cancer Antibody Pipeline Listed by Cofactor Binding Targets
  • Table 8: Cancer Antibody Pipeline Listed by Complement Activity Targets
  • Table 9: Cancer Antibody Pipeline Listed by Cytokine Activity Targets
  • Table 10: Cancer Antibody Pipeline Listed by DNA Topoisomerase Activity Targets
  • Table 11: Cancer Antibody Pipeline Listed by Extracellular Matrix Structural Constituent Targets
  • Table 12: Cancer Antibody Pipeline Listed by G-protein Coupled Receptor Activity Targets
  • Table 13: Cancer Antibody Pipeline Listed by Growth Factor Activity Targets
  • Table 14: Cancer Antibody Pipeline Listed by Hormone Activity Targets
  • Table 15: Cancer Antibody Pipeline Listed by Hydrolase Activity Targets
  • Table 16: Cancer Antibody Pipeline Listed by Intracellular Ligand-gated Ion Channel Activity Targets
  • Table 17: Cancer Antibody Pipeline Listed by Metallopeptidase Activity Targets
  • Table 18: Cancer Antibody Pipeline Listed by MHC Class I Receptor Activity Targets
  • Table 19: Cancer Antibody Pipeline Listed by Molecular Function Unknown Targets
  • Table 20: Cancer Antibody Pipeline Listed by Oxidoreductase Activity Targets
  • Table 21: Cancer Antibody Pipeline Listed by Peptide Hormone Targets
  • Table 22: Cancer Antibody Pipeline Listed by Protease inhibitor Activity Targets
  • Table 23: Cancer Antibody Pipeline Listed by Protein Binding Targets
  • Table 24: Cancer Antibody Pipeline Listed by Receptor Activity Targets
  • Table 25: Cancer Antibody Pipeline Listed by Receptor Binding Targets
  • Table 26: Cancer Antibody Pipeline Listed by Receptor Signaling Complex Scaffold Activity Targets
  • Table 27: Cancer Antibody Pipeline Listed by Receptor Signaling Protein Tyrosine Phosphatase Activity Targets
  • Table 28: Cancer Antibody Pipeline Listed by RNA-directed DNA polymerase Activity Targets
  • Table 29: Cancer Antibody Pipeline Listed by Serine-type Peptidase Activity Targets
  • Table 30: Cancer Antibody Pipeline Listed by T cell Receptor Activity Targets
  • Table 31: Cancer Antibody Pipeline Listed by Translation Regulator Activity Targets
  • Table 32: Cancer Antibody Pipeline Listed by Transmembrane Receptor Activity Targets
  • Table 33: Cancer Antibody Pipeline Listed by Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
  • Table 34: Cancer Antibody Pipeline Listed by Transporter Activity Targets
  • Table 35: Cancer Antibody Pipeline Listed by Unclassified Targets
  • Table 36: Antibody Drugs Targeting Signaling Pathways
  • Table 37: Signaling Pathway Analysis of Oncology Antibody Drug Targets
  • Table 38: Targets Linking Antibody Drugs to the Alpha6 Beta4 Integrin Signaling Pathway
  • Table 39: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Alpha6 Beta Integrin Signaling Pathway
  • Table 40: Targets Linking Antibody Drugs to the Androgen Receptor Signaling Pathway
  • Table 41: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Androgen Receptor Signaling Pathway
  • Table 42: Targets Linking Antibody Drugs to the B Cell Receptor Signaling Pathway
  • Table 43: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the B Cell Receptor Signaling Pathway
  • Table 44: Targets Linking Antibody Drugs to the EGFR1 Signaling Pathway
  • Table 45: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the EGFR Signaling Pathway
  • Table 46: Targets Linking Antibody Drugs to the IL-2 Signaling Pathway
  • Table 47: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-2 Signaling Pathway
  • Table 48: Targets Linking Antibody Drugs to the IL-4 Signaling Pathway
  • Table 49: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-4 Signaling Pathway
  • Table 50: Targets Linking Antibody Drugs to the IL-6 Signaling Pathway
  • Table 51: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-6 Signaling Pathway
  • Table 52: Targets Linking Antibody Drugs to the Kit Receptor Signaling Pathway
  • Table 53: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Kit Receptor Signaling Pathway
  • Table 54: Targets Linking Antibody Drugs to the Notch Signaling Pathway
  • Table 55: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Notch Signaling Pathway
  • Table 56: Targets Linking Antibody Drugs to the T Cell Receptor Signaling Pathway
  • Table 57: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the T Cell Receptor Signaling Pathway
  • Table 58: Targets Linking Antibody Drugs to the TGF-beta Receptor Signaling Pathway
  • Table 59: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the TGF-beta Receptor Signaling Pathway
  • Table 60: Targets Linking Antibody Drugs to the TNF-alpha Signaling Pathway
  • Table 61: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the TNF-alpha Signaling Pathway
  • Table 62: Targets Linking Antibody Drugs to the Wnt Signaling Pathway
  • Table 63: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Wnt Signaling Pathway
  • Table 64: Cell Surface Markers of Identified Cancer Stem Cells in Human Tumors
  • Table 65: Signaling Pathways Involved in Stem Cell Self-Renewal
  • Table 66: Immunoconjugated Antibody Targets According to Molecular Function of Target
  • Table 67: Immunoconjugated Antibody Pipeline According to Target
  • Table 68: Antibodies in Oncology Reported to Affect Angiogenesis
  • Table 69 Antibodies in Oncology Reported to Affect Apoptosis
  • Table 70: Antibody Drug Protein Kinase Targets Ranked by Probability of Carrying at Least One Driver Mutation, Conditional on the Gene-Specific Selection Pressures
  • Table 71: Antibodies in Oncology Reported to Act as Protein Kinase Inhibitors
  • Table 72: Cancer Indicaions by Number of Known Antibody Targets, Number of Antibody Drugs, and Highest Developmental Stage
  • Table 73: Antibody Pipeline by Targets in Basal Cell Cancer
  • Table 74: Antibody Pipeline by Targets in Biliary Cancer
  • Table 75: Antibody Pipeline by Targets in Bladder Cancer
  • Table 76: Antibody Pipeline by Targets in Bone Cancer
  • Table 77: Antibody Pipeline by Targets in Brain Cancer
  • Table 78: Antibody Pipeline by Targets in Breast Cancer
  • Table 79: Antibody Pipeline by Targets in Cervical Cancer
  • Table 80: Antibody Pipeline by Targets in Cervical Dysplasia
  • Table 81: Antibody Pipeline by Targets in Colorectal Cancer
  • Table 82: Antibody Pipeline by Targets in Endometrial Cancer
  • Table 83: Antibody Pipeline by Targets in Esophageal Cancer
  • Table 84: Antibody Pipeline by Targets in Fallopian Tube Cancer
  • Table 85: Antibody Pipeline by Targets in Gastrointestinal Cancers
  • Table 86: Antibody Pipeline by Targets in Head and Neck Cancer
  • Table 87: Antibody Pipeline by Targets in Leukemias
  • Table 88: Antibody Pipeline by Targets in Liver Cancer
  • Table 89: Antibody Pipeline by Targets in Lung Cancers
  • Table 90: Antibody Pipeline by Targets in Lymphomas
  • Table 91: Antibody Pipeline by Targets in Melanoma
  • Table 92: Antibody Pipeline by Targets in Mesothelioma
  • Table 93: Antibody Pipeline by Targets in Myelodysplastic syndrome
  • Table 94: Antibody Pipeline by Targets in Myelomas
  • Table 95: Antibody Pipeline by Targets in Nasopharyngeal Cancer
  • Table 96: Antibody Pipeline by Targets in Oesophageal Cancer
  • Table 97: Antibody Pipeline by Targets in Ovarian Cancer
  • Table 98: Antibody Pipeline by Targets in Pancreatic Cancer
  • Table 99: Antibody Pipeline by Targets in Peritoneal Cancer
  • Table 100: Antibody Pipeline by Targets in Prostate Cancer
  • Table 101: Antibody Pipeline by Targets in Renal Cancers
  • Table 102: Antibody Pipeline by Targets in Sarcomas
  • Table 103: Antibody Pipeline by Targets in Thyroid Cancer
  • Table 104: Expression Profiles of Antibody Drug Targets in Oncology
  • Table 105: The Stage System
  • Table 106: Risk Factors
  • Table 107: List of Approved Drugs and Their Mechanisms of Action.
  • Table 108: Hormonal Treatment Strategies
  • Table 109: Adjuvant Systemic Treatment Options for Women With Axillary Node-Negative Breast Cancer
  • Table 110: Treatment Options for Women With Axillary Node-Positive Breast Cancer
  • Table 111: Chemotherapy Drugs and Regimen
  • Table 112: Summay of Drugs Involved in Breast Cancer Therapy
  • Table 113: Short Facts Tamoxifen
  • Table 114: Short Facts Anastrozole
  • Table 115: Short Facts Letrozole
  • Table 116: Short Facts Exemestane
  • Table 117: Short Facts Goserelin
  • Table 118: Short Facts Fulvestrant
  • Table 119: Short Facts Trastuzumab
  • Table 120 Cancer Immunotherapy Strategies
  • Table 121: Progress on Ixabepilone
  • Table 122: Progress on CCI-779
  • Table 123: Progress on Fenretinide
  • Table 124: Progress on Lapatinib
  • Table 125: Progress on Bevacizumab
  • Table 126: Progress on Theratope
  • Table 127: Summary of Mid-Stage to Late stage Investigational Agents Under Development
  • Table 128: Summary of Breast Cancer Early Stage Pipeline
  • Table 129: The TNM System
  • Table 130: Lifestyle factors
  • Table 131: Historical Summary of Clinical Studies on Patients with Late Stage Disease
  • Table 132: Short Facts Abarelix
  • Table 133: Short Facts Bicalutamide
  • Table 134: Short Facts Carboplatin
  • Table 135: Short Facts Docetaxel
  • Table 136: Short Facts Mitoxantrone
  • Table 137: Short Facts Flutamide
  • Table 138: Short Facts Goserelin
  • Table 139: Short Facts Histrelin
  • Table 140: Short Facts Lanreotide
  • Table 141: Short Facts Leuprolide
  • Table 142: Short Facts Nilutamide
  • Table 143: Short Facts Estramustine
  • Table 144: Summary of Recent Clinical Studies on Patients with Late Stage Disease
  • Table 145: Ongoing Late Stage Clinical Studies
  • Table 146: Cancer Immunotherapy Strategies
  • Table 147: Near Term Progress Toremifene
  • Table 148: Near Term Progress Bevacizumab
  • Table 149: Near Term Progress Oblimersen
  • Table 150: Near Term Progress R-flurbiprofen
  • Table 151: Near Term Progress APC8015
  • Table 152: Near Term Progress Satraplatin
  • Table 153: Near Term Progress GVAX
  • Table 154: Near Term Progress Exisulind
  • Table 155: Summary of Prostate Cancer Late Stage Pipeline
  • Table 156: Paclitaxel
  • Table 157: Epothilone
  • Table 158: Ixabepilone
  • Table 159: PTK/ZK
  • Table 160: Arsenic trioxide
  • Table 161: Retinoic Acid
  • Table 162: Imatinib
  • Table 163: Bortezomib
  • Table 164: Sorafenib
  • Table 165: Doxorubicin
  • Table 166: Summary of Prostate Cancer Early Stage Pipeline
• 3.3 List of Boxes
  • Box 1: Ongoing Phase III Studies Anastrozole
  • Box 2: Ongoing Phase III Studies Letrozole
  • Box 3: Ongoing Phase III Studies Exemestane
  • Box 4: Ongoing Phase III Studies Goserelin
  • Box 5: Ongoing Phase III Studies Fulvestrant
  • Box 6: Ongoing Phase III Studies Trastuzumab
  • Box 7: The TRAIL Receptor family
  • Box 8: The Bcl-2 family of proteins
  • Box 9: Quick Facts - BMS-247550
  • Box 10: Quick Facts - Temsirolimus
  • Box 11: Quick Facts - SDX-105
  • Box 12: Quick Facts - 4HPR
  • Box 13: Quick Facts - Lapatinib
  • Box 14: Quick Facts - Bevacizumab
  • Box 15: Quick Facts - Theratope
  • Box 16: Erlotinib
  • Box 17: Gefitinib
  • Box 18: Imatinib
  • Box 19: Pemetrexed
  • Box 20: NX473
  • Box 21: Lonafarnib
  • Box 22: Tipifarnib
  • Box 23: Bortezomib
  • Box 24: Arzoxifene
  • Box 25: Patupilone
  • Box 26: KOS-862
  • Box 27: Southwest Oncology Group Study 99-16 Design
  • Box 28: TAX 327 Study Design
  • Box 29: The TRAIL Receptor family
  • Box 30: The Bcl-2 family of proteins
  • Box 31: Quick Facts - Toremifene
  • Box 32: Quick Facts - Bevacizumab
  • Box 33: Quick Facts - Genasense
  • Box 34: Quick Facts - R-flurbiprofen
  • Box 35: Quick Facts - Provenge
  • Box 36: Quick Facts - Satraplatin
  • Box 37: Quick Facts - GVAX
  • Box 38: Quick Facts - Exisulind
  • Box 39: Quick Facts - Vapreotide
  • Box 40: Quick Facts - DCVax